Patent intelligence · US
US 12172969
Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof
Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof
Patent details — US 12172969
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 24, 2024
- Expiration
- Dec 19, 2044
- Applicant
- EVOFEM BIOSCIENCES, INC.
- Claims
- 23
- CPC classes
- A61K, A61K31/4164, A61K31/565, A61K31/567
Quick answer
US 12172969 (Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof) is held by EVOFEM BIOSCIENCES, INC.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- EVOFEM BIOSCIENCES, INC.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K31/4164, A61K31/565, A61K31/567, A61K31/57
More from EVOFEM BIOSCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12280037
Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
granted -
US 11992472
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 11439610
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 11419835
Method of treatment and prevention of bacterial vaginosis
granted -
US 11337989
Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
granted -
US 10568855
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 9566232
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted
Frequently asked questions
What is US patent 12172969?
US 12172969 (Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof) is held by EVOFEM BIOSCIENCES, INC.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12172969?
EVOFEM BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 12172969 expire?
Our index shows an expiration date of Dec 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.